A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
- Sponsor:
- NRG
- Sponsor Study ID:
- NRG-GY037
- CTO #:
- 104285
- NCT Number:
- NCT07061977
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Cervix Uteri
- Study Objectives:
- To determine whether induction IO and chemotherapy prior to CCRT+IO improves progression-free survival (PFS) compared to CCRT+IO alone.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Orr, Brian, at orrb@musc.edu .
- Study Coordinator, Knox, Crystal, at knoxc@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina